Existing research has validated in vivo CRISPR/Cas9 therapeutics as novel treatment modalities, resulting in significant phenotypic amelioration—including hyperkeratosis (with 50% epidermal thinning), abnormal melanin deposition, and dysregulated stress keratins (K6/K16) while restoring regular differentiation/proliferation markers with minimal off-target effects [18]. Here, KRT16 is linked to Hyperkeratosis.